MedTrace Logo

Early Post-Operative Enteral Feeding in Patients With Advanced Epithelial Ovarian Cancer

NCT00850772 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 109

Last updated 2014-06-12

No results posted yet for this study

Summary

Ovarian cancer patients are often at risk of malnutrition because of weight loss, lack of appetite and reduced food intake. Being malnourished can contribute to the incidence and severity of cancer treatment side effects and increase the risk of infection. Currently patients with advanced ovarian cancer do not receive early nutrition using a feeding tube.

The purpose of this study is to compare enteral nutrition along with standard post-surgery care against current standard post-operative care alone. This study will see if early nutrition using a feeding tube has an impact on length of hospital admission, recovery from surgery, complications from surgery, nutritional status and ultimately a reduction in treatment costs in people with Advanced Epithelial Ovarian Cancer (EOC). Primary Peritoneal Cancer (PPC) or Fallopian Tube Cancer. Nutritional support has been shown to ;

* Prevent and treat under-nutrition,
* Enhance anti-tumour treatment effects,
* Reduce adverse effects of anti-tumour therapies,
* Improve quality of life.

Conditions

Interventions

DIETARY_SUPPLEMENT

Early post-operative enteral feeding

During primary surgical treatment an enteral feeding tube will be inserted through the patient's nose into their small bowel. Enteral feeding will commence 4 hours following return to ward from surgery. Feeding will start at a rate of 40 ml/hr for the first 24 hours, and then increased to goal weight. Goal will be calculated by 125 kiloJoules/kilogram adjusted body weight.

Sponsors & Collaborators

  • Cancer Australia Priority-driven Collaborative Cancer Research Scheme

    collaborator UNKNOWN

  • The University of Queensland

    collaborator OTHER

  • Queensland Centre for Gynaecological Cancer

    lead OTHER_GOV

Principal Investigators

  • Andreas Obermair, MD FRANZCOG CGO · Queensland Centre for Gynaecological Cancer

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2013-08-31
Completion
2013-08-31

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00850772 on ClinicalTrials.gov